Skip to main content
Equibles
VIR logo

VIR · Vir Biotechnology, Inc. · Earnings Call Transcripts & Audio

Track VIR — free

Use VIR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VIR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.62 +0.04 (+0.38%) At close · Sep 11
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.80B
Shares
169.22M

Vir Biotechnology, Inc. Earnings Call Transcripts

Quarterly earnings calls for Vir Biotechnology, Inc. (VIR), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $3.80M −$194.78M '23 Q2 23-08-03 ▼99.3% $2.64M −$163.41M '23 Q3 23-11-02 ▼66% $16.79M −$115.92M '23 Q4 24-02-22 ▼10.5% $56.38M −$65.28M '24 Q1 24-05-02 ▼19% $3.08M −$138.38M '24 Q2 24-08-01 ▼9.8% $2.38M −$213.72M '24 Q3 24-10-31 ▼26.3% $12.37M −$104.59M '24 Q4 25-02-26 ▼94.6% $3.03M −$120.97M '25 Q1 25-05-07 ▼60.5% $1.21M −$110.96M '25 Q2 25-08-06 ▼89.9% $240,000 −$163.14M '25 Q3 25-11-05 ▲417.8% $64.07M −$42.92M '25 Q4 26-02-23 ▼101% $ −$125.69M '26 Q1 26-05-06 LATEST ▲19582.5% $238.95M $80.08M '26 Q2 26-08-05
Conference
Investor event
2026-09-14
Vir Biotechnology, Inc. (VIR) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Confident tone Hepatitis Delta registrational program (Eclipse trials) HDV disease awareness, testing and diagnosis Oncology pipeline - VIR-5500 PSMA T-cell engager
Revenue
$238.95M
▲ 19582.5% YoY
Diluted EPS
$0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Confident tone Astellas collaboration / VIR-5500 prostate cancer Hepatitis delta (tobevibart + elebsiran) and ECLIPSE trials Other T cell engager pipeline (VIR-5818, VIR-5525)
Revenue
$
▼ 101% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Confident tone Strategic collaboration with Astellas Dose escalation and therapeutic index optimization Pro-X10 platform validation
Revenue
$64.07M*
▲ 417.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
Confident tone Eclipse Phase 3 Hepatitis Delta Program VIR-5500 PSMA T-cell Engager Solstice Phase 2 Data and ASLD Presentation
Revenue
$240,000
▼ 89.9% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript
Confident tone T Cell Engager Oncology Portfolio (PRO-XTEN) Hepatitis Delta / ECLIPSE Program PSMA / VIR-5500 Prostate Cancer
Revenue
$1.21M
▼ 60.5% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Confident tone Hepatitis Delta (Eclipse Phase 3) Program Pro-X10 Oncology T-cell Engager Platform Hepatitis B Program
Revenue
$3.03M
▼ 94.6% YoY
Diluted EPS
$-0.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Confident tone T-cell engager oncology platform and PRO-XTEN Hepatitis B functional cure and partnership strategy Hepatitis delta (HDV) program and ECLIPSE Phase III
Revenue
$12.37M*
▼ 26.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
Confident tone Sanofi licensing deal and T-cell engagers Hepatitis B (HBV) functional cure program Upcoming investor events and AASLD data
Revenue
$2.38M
▼ 9.8% YoY
Diluted EPS
$-1.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript
Confident tone Sanofi license agreement / masked T-cell engagers Cancer therapeutics landscape and unmet need Revised 2024 expense guidance
Revenue
$3.08M
▼ 19% YoY
Diluted EPS
$-1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Positive tone Hepatitis delta / SOLSTICE trial Hepatitis B functional cure / MARCH trial Regulatory engagement and Phase III planning
Revenue
$56.38M
▼ 10.5% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
Confident tone Financial position and capital allocation Leadership transition (CMO departure) Influenza antibodies / GSK collaboration termination
Revenue
$16.79M*
▼ 66% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
Revenue
$2.64M
▼ 99.3% YoY
Diluted EPS
$-1.22
▼ 193.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Vir Biotechnology, Inc. (VIR) Q2 2023 Earnings Call Transcript
Revenue
$3.80M
Diluted EPS
$-1.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–14 of 14 earnings calls
Key facts CIK 1706431 CUSIP 92764N102 13F (30d) 78 filings 78 filers Visit website Investor relations